Clinical Trials Logo

Down Syndrome clinical trials

View clinical trials related to Down Syndrome.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT04373616 Withdrawn - Down Syndrome Clinical Trials

A Study of ACI-24 in Adults With Down Syndrome

Start date: October 2021
Phase: Phase 2
Study type: Interventional

This study is a prospective multicenter, placebo-controlled, double-blind, randomized study to assess the effect of one dose ACI-24 versus placebo over a 74-week treatment period and 26-week safety follow-up period.

NCT ID: NCT03087500 Withdrawn - Down Syndrome Clinical Trials

Physiological Abnormalities Associated With Down Syndrome

Start date: October 2017
Phase:
Study type: Observational

The overall goal of this study is to evaluate biomarkers of oxidative stress, mitochondrial function, and DNA methylation (epigenetics) in order to determine the extent to which these biomarkers are related to cognitive, behavioral and adaptive function in Down Syndrome. The inter-relationship between measurable biomarkers and functional/cognitive abilities will move beyond genetics to provide unprecedented new knowledge and a broader understanding of the underlying pathophysiology and abnormal gene expression induced by trisomy 21.

NCT ID: NCT00891917 Withdrawn - Down Syndrome Clinical Trials

Liq-NOL Efficacy in Pediatric Patients With Down Syndrome

Start date: January 2005
Phase: Phase 2
Study type: Interventional

The purpose of this study is to measure the effects of LiQ-NOL supplementation on language production using the Clinical Evaluation of Language Fundamentals test, language sampling using the mean length of utterance test, and speech articulation using the Goldman-Fristoe Test of Articulation.

NCT ID: NCT00411281 Withdrawn - Leukemia Clinical Trials

Low-Dose Cytarabine in Treating Infants With Down Syndrome and Transient Myeloproliferative Disorder

Start date: March 2006
Phase: Phase 3
Study type: Interventional

RATIONALE: Drugs used in chemotherapy, such as cytarabine, work in different ways to stop the growth of abnormal cells, either by killing the cells or by stopping them from dividing. Giving low-doses of cytarabine may be an effective treatment for Down syndrome and transient myeloproliferative disorder. Sometimes the disease may not need treatment until it progresses. In this case, observation may be sufficient. PURPOSE: This phase III trial is studying low-dose cytarabine to see how well it works in treating infants with Down syndrome and transient myeloproliferative disorder.